# A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT07461181** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors

## Interventions

- **BIOLOGICAL:** CS01 (an anti-OX40 antibody)

## Key facts

- **NCT ID:** NCT07461181
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07461181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07461181, "A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07461181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*